Hormonal
Tirzepatide (5, 10, and 15 mg once-weekly) provides superior glycemic control (HbA1c reduction) and greater body weight loss compared to placebo, GLP-1 receptor agonists, and basal insulin in adults with type 2 diabetes.
Tirzepatide is a once-weekly injection that lowers blood sugar and helps with weight loss more effectively than existing GLP-1 drugs (like semaglutide) and basal insulin. It works by mimicking two gut hormones (GIP and GLP-1). While it is very effective, it can cause stomach issues like nausea and diarrhea, which might lead some people to stop taking it, especially at higher doses. It does not increase the risk of low blood sugar (hypoglycemia) on its own.
A dose-dependent superiority in lowering HbA1c was evident with all three tirzepatide doses vs all comparators... Tirzepatide was more efficacious in reducing body weight; reductions vs GLP-1 RAs ranged from 1.68 kg with tirzepatide 5 mg to 7.16 kg with tirzepatide 15 mg.
Why this rating
Systematic review and meta-analysis of 7 RCTs with 6609 participants.
Source
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
Thomas Karagiannis et al. · Diabetologia · 2022
DOI 10.1007/s00125-022-05715-4
More from this paper
- Tirzepatide does not increase the risk of hypoglycemia compared to placebo and has a lower risk compared to basal insulin.Strong
- Tirzepatide is associated with a higher incidence of gastrointestinal adverse events (nausea, vomiting, diarrhea) compared to placebo and basal insulin, which can lead to treatment discontinuation.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →